

On page 12, line 21, after "Nucleotide sequence", please insert --(SEQ ID NO:3)--.

On page 12, lines 21 and 22, after "amino acid sequence", please insert --(SEQ ID NO:4)--.

On page 12, line 23, after "Nucleotide sequence", please insert --(SEQ ID NO:5)--.

On page 12, lines 23 and 24, after "amino acid sequence", please insert --(SEQ ID NO:6)--.

On page 12, line 25, after "Nucleotide sequence", please insert --(SEQ ID NO:7)--.

On page 12, lines 25 and 26, after "amino acid sequence", please insert --(SEQ ID NO:8)--.

On page 12, line 27, after "Nucleotide sequence", please insert --(SEQ ID NO:9)--.

On page 12, lines 27 and 28, after "amino acid sequence", please insert --(SEQ ID NO:10)--.

On page 12, line 29, after "Nucleotide sequence", please insert --(SEQ ID NO:11)--.

On page 12, lines 29 and 30, after "amino acid sequence", please insert --(SEQ ID NO:12)--.

On page 33, line 10, please delete the phrase "FIGS. 8, 12, 15, 18, 22, 28, 31, and 35", and insert in its place --FIGS. 1-5--.

On page 36, in Table 1, in the second column from the left, entitled "Seq. ID #", in the third row, delete "2" and insert in its place --3--; in the fourth row, delete "3" and insert in its place --5--; in the fifth row, delete "4"

and insert in its place --7--; and in the sixth row, delete "5" and insert in its place --9--.

On page 110, line 35, after "rev-T<sub>11</sub>XC", please insert --(SEQ ID NO:13)--; after "for-GTGAGGCGTC", please insert --(SEQ ID NO:14)--.

On page 110, line 36, after "rev-T<sub>11</sub>XC", please insert --(SEQ ID NO:13)--; after "for-TGGACCGGTG", please insert --(SEQ ID NO:15)--.

On page 120, line 9, after "for-T<sub>11</sub>XA", please insert --(SEQ ID NO:16)--; after "rev-AGACGTCCAC", please insert --(SEQ ID NO:17)--.

On page 120, line 10, after "for-T<sub>11</sub>XA", please insert --(SEQ ID NO:16)--; after "rev-ACTTCGCCAC", please insert --(SEQ ID NO:18)--.

On page 120, line 11, after "for-T<sub>11</sub>XC", please insert --(SEQ ID NO:13)--; after "rev-TCGGACGTGA", please insert --(SEQ ID NO:19)--.

On page 124, line 33, after "YTDTGKASGNLETKYK", please insert --(SEQ ID NO:43)--.

On page 124, line 34, after "TGKKSGKCLKASYKRD", please insert --(SEQ ID NO:44)--.

On page 133, line 35, please delete "19944", and insert in its place --1994--.

On page 134, line 29, after "5'-CATTTTCATTTCATACAA-3'", please insert --(SEQ ID NO:20)--.

On page 134, line 32, after "5'-CATTTTCATTTCATACAATATATG-3'", please insert

--(SEQ ID NO:21)--.

On page 134, line 35, after

"5'-CATTTTCATTTTCATACAATATATGGCCTTT-3'", please insert

--(SEQ ID NO:22)--.

On page 135, line 1, after

"5'-CATTTTCATTTTCATACAATATATGGCCTTTTGTGGC-3'", please insert

--(SEQ ID NO:23)--.

On page 135, line 5, after

"5'-GGACATTTTCATTTTCATACAATATATGGCCTTTTGT-3'", please insert

--(SEQ ID NO:24)--.

On page 135, line 9, after

"5'-TTCATTTTCATACAATATATGGCCTTTTGT-3'", please insert

--(SEQ ID NO:25)--.

On page 135, line 13, after

"5'-TCATACAATATATGGCCTTTTGT-3'", please insert

--(SEQ ID NO:26)--.

On page 135, line 16, after

"5'-AATATATGGCCTTTTGT-3'", please insert --(SEQ ID NO:27)--.

On page 135, line 21, after

"5'-CATGCGGGGCGAGGAGG-3'", please insert --(SEQ ID NO:28)--.

On page 135, line 24, after

"5'-CATGCGGGGCGAGGAGGCGAGGA-3'", please insert

--(SEQ ID NO:29)--.

On page 135, line 27, after

"5'-CATGCGGGGCGAGGAGGCGAGGAGAAAAG-3'", please insert

--(SEQ ID NO:30)--.

On page 135, line 31, after

"5'-CATGCGGGGCGAGGAGGCGAGGAGAGAAAAGTCGTTT-3'", please insert  
--(SEQ ID NO:31)--.

On page 135, line 35, after

"5'-GAACATGCGGGGCGAGGAGGCGAGGAGAGAAAAGTCG-3'", please insert  
--(SEQ ID NO:32)--.

On page 136, line 1, after

"5'-GCGGGGCGAGGAGGCGAGGAGAGAAAAGTCG-3'", please insert  
--(SEQ ID NO:33)--.

On page 136, line 5, after

"5'-CGAGGAGGCGAGGAGAGAAAAGTCG-3'", please insert  
--(SEQ ID NO:34)--.

On page 136, line 8, after

"5'-GGCGAGGAGAGAAAAGTCG-3'", please insert --(SEQ ID NO:35)--.

On page 136, line 16, after

"5'-CAAAGCNGNXXXXNCNGAGNAGUC-3'", please insert  
--(SEQ ID NO:36)--.

On page 137, lines 4 and 5, after

"5'-GGUGGAGCCCCAGGGCAUUACCUCAAAGCNGNXXXXNCNGAGNAGUCGUGGGCAAGGU  
GGGCACUCAGGUGGG-3'", please insert --(SEQ ID NO:37)--.

On page 137, lines 7 and 8, after

"5'-GUGUCUCUAUGGGUUUGCCCAAAGCNGNXXXXNCNGAGNAGUCUCUGGACAUUUCAUU  
UCAUAC-3'", please insert --(SEQ ID NO:38)--.

On page 137, lines 10 and 11, after

"5'-GGCCCUCUCGCCGUCGGGCUCCUUGCUGAGCAAAGCNGNXXXXNCNGAGNAGUCGAUG  
CCGAAGCCGAUCUUGCUGCGCG-3'", please insert --(SEQ ID NO:39)--.

On page 137, lines 17 and 18, after

"5'-CGUUUGCCUGCUAAGGAGCGAACAAAGCNGNXXXXNCNGAGNAGUCGAUGUUUCUUUG  
UGAGUCGGGCGCCG-3'", please insert --(SEQ ID NO:40)--.

On page 137, lines 20 and 21, after  
"5'-CGCCGGACGAGCGCAGAUUGGUCCUGAACAAAGCNGNXXXXNCNGAGNAGUCCG  
GGGCGAGGAGGCGAGGAGAAAAGUCG-3'", please insert  
--(SEQ ID NO:41)--.

On page 137, lines 24 and 25, after  
"5'-GGAGUAAGGAGGGGGGGGAGACUCUAGUUCGCAAAGCNGNXXXXNCNGAGNAGUCAGU  
CGGCUAAGGUGAUGGGGGUUGCAGCACACC-3'", please insert  
--(SEQ ID NO:42)--.

IN THE CLAIMS:

Please cancel Claims 1-69, without prejudice.

Please add new claims 70-96 as follows:

*Sub.B1*  
-- 70. (new) An isolated polynucleotide comprising a  
nucleotide sequence: (a) encoding a polypeptide having the  
fchd605 amino acid sequence set forth in SEQ ID NO:10; or (b)  
which is the complement of (a).

*a1*  
71. (new) An isolated polynucleotide comprising the  
fchd605 nucleotide sequence: (a) set forth in SEQ ID NO:9; or  
(b) which is the complement of (a).

72. (new) An isolated polynucleotide which hybridizes  
under highly stringent conditions to the polynucleotide of  
Claim 70.

73. (new) An isolated polynucleotide which hybridizes under moderately stringent conditions to the polynucleotide of Claim 70, wherein the polynucleotide is differentially expressed in a cardiovascular disease state.

Sub B2  
74. (new) An isolated polynucleotide comprising the nucleotide sequence: (a) of the fchd605 polypeptide coding region, as set forth from nucleotide residue number 1 to 468 of SEQ ID NO:9; or (b) which is the complement of (a).

all can't  
75. (new) An isolated polynucleotide which hybridizes under highly stringent conditions to the polynucleotide of Claim 74.

76. (new) An isolated polynucleotide which hybridizes under moderately stringent conditions to the polynucleotide of Claim 74, wherein the polynucleotide is differentially expressed in a cardiovascular disease state.

Sub B3  
77. (new) An isolated polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76 which is DNA.

78. (new) The isolated polynucleotide of Claim 77 which is cDNA.

79. (new) The isolated polynucleotide of Claim 77 which is genomic DNA.

80. (new) The isolated polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76 which is RNA.

81. (new) The isolated polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76 which further comprises a label.

82. (new) A polynucleotide vector containing the polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76.

83. (new) An expression vector containing the polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76 in operative association with a nucleotide regulatory element which controls expression of the polynucleotide in a host cell.

84. (new) A genetically engineered host cell containing the polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76 in association with nucleotide sequences exogenous to the polynucleotide.

85. (new) A genetically engineered host cell containing the polynucleotide of Claim 70, 71, 72, 73, 74, 75, or 76 in operative association with a nucleotide regulatory element exogenous to the polynucleotide, wherein the regulatory element controls expression of the polynucleotide in the host cell.

Sub. B4  
86. (new) The genetically engineered host cell of Claim 85 which is prokaryotic.

87. (new) The genetically engineered host cell of Claim 85 which is eukaryotic.

88. (new) A method of producing a polypeptide fchd605 gene product, comprising the steps of:

- Al cont
- (a) growing the genetically engineered host cell of Claim 86 in a culture; and
  - (b) collecting the polypeptide gene product from the culture.

89. (new) A method of producing a polypeptide fchd605 gene product, comprising the steps of:

- (a) growing the genetically engineered host cell of Claim 87 in a culture; and
- (b) collecting the polypeptide gene product from the culture.

90. (new) An isolated polypeptide having the fchd605 amino acid sequence set forth in SEQ ID NO:10.

91. (new) An isolated polypeptide encoded by a polynucleotide which hybridizes under highly stringent conditions to the complement of the fchd605 nucleotide sequence set forth in SEQ ID NO:9.



92. (new) An isolated polypeptide encoded by a polynucleotide which hybridizes under moderately stringent conditions to the complement of the fchd605 nucleotide sequence set forth in SEQ ID NO:9, wherein the polynucleotide is differentially expressed in a cardiovascular disease state.

93. (new) The polypeptide of Claim 91 or 92 wherein the polypeptide contains the amino acid sequence set forth in SEQ ID NO:10.

*Al  
concluded*

94. (new) An isolated polypeptide encoded by a polynucleotide which hybridizes under highly stringent conditions to the complement of the fchd605 polypeptide coding region, as set forth from nucleotide residue number 1 to 468 of SEQ ID NO:9.

95. (new) An isolated polypeptide encoded by a polynucleotide which hybridizes under moderately stringent conditions to the complement of the fchd605 polypeptide coding region, as set forth from nucleotide residue number 1 to 468 of SEQ ID NO:9, wherein the polynucleotide is differentially expressed in a cardiovascular disease state.

96. (new) The polypeptide of Claim 94 or 95 wherein the polypeptide contains the amino acid sequence set forth in SEQ ID NO:10.--